McAndrews

About

  • The Orange Book blog team are a group of attorneys with McAndrews, Held and Malloy, which is a full-service IP firm representing both brands and generics in various aspects of IP law. This blog does not provide legal advice. If you are seeking legal advice, please contact the author directly.

Disclaimer

  • Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is not edited by McAndrews, Held & Malloy, Ltd. ("MHM") or its clients. The views expressed are solely those of the authors, and may not reflect the views of MHM or its clients. No part of Orange Book Blog--whether information, commentary, or other--may be attributed to MHM or its clients. MHM represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MHM clients. Orange Book Blog will always strive to be unbiased. All information on Orange Book Blog should be double-checked for its accuracy and current applicability.

« FDA Announces New "First Generics" Policy for Review of ANDAs | Main | FTC and Warner Chilcott Settle Antitrust Case Over Ovcon 35 »

October 23, 2006

Federal Circuit Denies Ranbaxy's Request for Rehearing in Lipitor Case

Pfizer announced in a press release today that the Federal Circuit has denied Ranbaxy's request for rehearing in the Lipitor patent case between the two companies.  On August 2nd of this year, a panel of the Federal Circuit invalidated one of two Pfizer patents on atorvastatin, the active ingredient in Lipitor, but upheld the other (click here for Aug. 2 opinion).  Ranbaxy had appealed that decision.

The Pfizer patent that was previously declared valid and infringed is set to expire in March, 2010.  The patent declared invalid will expire in June, 2011, but Pfizer has indicated that it will seek to correct the defect in that patent through a reissue patent application.

Ranbaxy was the first generic drug company to file an ANDA challenging Pfizer's patents on atorvastatin, and was considered especially agressive for doing so.  Lipitor is the world's best-selling pharmaceutical, with sales last year of $12 billion.

RELATED READING:

Posted by in Paragraph IV Cases |

Comments

Verify your Comment

Previewing your Comment

Posted by:  | 

This is only a preview. Your comment has not yet been posted.

Working...
Your comment could not be posted. Error type:
Your comment has been saved. Comments are moderated and will not appear until approved by the author. Post another comment

The letters and numbers you entered did not match the image. Please try again.

As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

Having trouble reading this image? View an alternate.

Working...

Post a comment

Comments are moderated, and will not appear until the author has approved them.

Your Information

(Name is required. Email address will not be displayed with the comment.)